Press Release

TaiGen files US IND for its influenza antiviral TG-1000

TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.

A Phase 1 trial for in China was initiated by TaiGen in July 2020 and has successfully completed the first 4 groups in the single ascending dose part. A Phase 2 protocol has also been submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing last month.

“We are excited about the IND filing in the US for the internally developed TG-1000 which has the potential to be a single dose treatment for influenza,” said Kuo-Lung Huang, the Chairman and CEO of TaiGen, “TG-1000 IND filing demonstrates yet again TaiGen’s capacity and experience in research and development of NCEs.”

About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and market-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to TG-1000, TaiGen has three other in-house discovered NCEs: Taigexyn®, a novel non-fluorinated quinolone available in both oral and intravenous formulations, TG-3000, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, and Furaprevir, a HCV protease inhibitor for treatment of chronic hepatitis infection. Taigexyn® is already on the market in the mainland China and Taiwan, TG-3000 has completed Phase 2 clinical studies, and Furaprevir is currently in Phase 3 clinical development.

SOURCE TaiGen

Medika Life

Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Recent Posts

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

Craig Martin is a strategic chameleon in health innovation. He is equally at home in…

1 week ago

The Silent Additive: What Singapore Street Food Taught Me About Ultra-Processed America

I Ate More. I Weighed Less. In Malaysia, I ate like a poet unchained. Noodles…

1 week ago

The Algorithm That Gave Me Pause Tonight and “Hooked” Me

I had never envisioned a computer responding to me and “telling” me that it had…

1 week ago

Why Israel’s Brilliant Climate Solutions Are Still Invisible

If you work in climate or environmental innovation, you’ve probably felt the shift: it’s getting…

2 weeks ago

The Surprising Health Benefits of Walking on Uneven Ground — And Why You Should Start Today

Most people walk to relax. I came to Borneo to let the ground fight back.…

2 weeks ago

Human First: Reclaiming Empathy in Our Love Affair with Health Tech

[Reprinted with permission by By Light-it, in collaboration with Digital Health Insider] We are a…

2 weeks ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More